

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司**  
**AIDIGONG MATERNAL & CHILD HEALTH LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 286)**

## **ADDITIONAL RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcements of the Company dated 13 March 2025, 18 March 2025, 2 April 2025 and 2 July 2025 respectively (collectively, the “**Announcements**”) in relation to, among others, the guidance for the resumption of trading in the shares of the Company (the “**Shares**”) set by the Stock Exchange on 12 March 2025 (the “**Initial Resumption Guidance**”) and the resignation of Mr. Shan Guoxin as an independent non-executive director of the Company. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as those defined in the Announcements.

## **ADDITIONAL RESUMPTION GUIDANCE**

As disclosed in the Company's announcement dated 2 July 2025, following the resignation of Mr. Shan as an independent non-executive Director with effect from 2 July 2025, the composition of the Board comprises four executive Directors, one non-executive Director and two independent non-executive Directors and hence the number of the independent non-executive Directors and the members of the Audit Committee has fallen below the minimum number required under the aforesaid Rules 3.10(1), 3.10A and 3.21 of the Listing Rules.

On 3 July 2025, the Company received a letter from the Stock Exchange setting out additional guidance for the resumption of trading in the Shares on the Stock Exchange (the "**Additional Resumption Guidance**", together with the Initial Resumption Guidance, the "**Resumption Guidance**"):

- re-comply with Rules 3.10(1), 3.10A and 3.21 of the Listing Rules.

The Stock Exchange also indicated that it may modify the Resumption Guidance and/or give further guidance as and when appropriate.

The Company will make further announcement(s) in relation to the above matters as and when appropriate and in accordance with the requirements of the Listing Rules to keep the Shareholders and the Company's potential investors informed of the latest progress in complying with the Resumption Guidance.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Wong Wing Cheung**  
*Company Secretary*

Hong Kong, 4 July 2025

*As at the date of this announcement, the Board comprises Mr. Huang Wenhua, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Lee Kar Lung as a non-executive Director; Mr. Chu Pui Ki Dickson and Mr. Wang Bin as independent non-executive Directors.*